Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer | SpringerLink
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
A Overall survival (OS) for the entire cohort. The median OS is... | Download Scientific Diagram
Overall survival (OS) of all patients. The median OS is 26 months (95 %... | Download Scientific Diagram
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial | Nature Medicine
Efficacy Data in Metastatic Colorectal Carcinoma | STIVARGA® (regorafenib) Global HCP Website
Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center | Journal of the Egyptian National Cancer Institute | Full Text
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
The median OS of the patients. OS, overall survival. | Download Scientific Diagram
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial | Nature Communications
The median OS of the patients. OS, overall survival. | Download Scientific Diagram
Time-dependent endpoints as predictors of overall survival in multiple myeloma | BMC Cancer | Full Text
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?
Brian Rini, MD (@brian_rini) / Twitter
Median OS vs Hazard Ratio | Stivarga Global Website
Efficacy Data | Xofigo® (Radium Ra 223 Dichloride)
Kaplan-Meier plots for survivals. In Figure 2A, a median OS of 9.1... | Download Scientific Diagram
Comparison of median OS (overall survival) and PFS (progression free... | Download Scientific Diagram
Time-dependent endpoints as predictors of overall survival in multiple myeloma | BMC Cancer | Full Text
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer | SpringerLink